Revolutionizing Diabetic Retinopathy Screening: Remidio's AI Solution Gains Regulatory Approval

Diabetic retinopathy (DR) poses a major threat to individuals with diabetes worldwide, leading to irreversible blindness if untreated. Remidio, a med-tech company, received regulatory approval for its Medios DR AI, an offline AI solution that screens for DR. This technology is pivotal in improving healthcare accessibility in India's remote areas and potentially across the globe.

Diabetic retinopathy (DR), a complication affecting one in three individuals with diabetes globally, can lead to irreversible blindness if left untreated. With the diabetic population projected to reach 642 million by 2040, healthcare systems are anticipated to face significant strain.

India, for instance, requires nearly 125 million individuals with diabetes (PWDs) to be screened annually for DR. However, with just one ophthalmologist per 100,000 patients, decentralizing screening to include primary care physicians is crucial. In contrast, the UK has successfully utilized retinal cameras and teleophthalmology in primary care to prevent and eliminate DR.

Remidio, a Bangalore-based company with offices in India, the US, and Singapore, has received CDSCO approval for its Medios DR AI, which is accompanied by portable retinal cameras. This offline AI detects referable DR without internet access and has gained traction in some of India's most remote areas. Remidio's technology is a significant milestone in India's regulatory landscape and aims to bring essential eye care to underserved communities.

(With inputs from agencies.)